James Collins - Synlogic CoFounder Board
| SYBX Stock | USD 1.36 0.05 3.55% |
Insider
James Collins is CoFounder Board of Synlogic
| Age | 58 |
| Address | 301 Binney Street, Cambridge, MA, United States, 02142 |
| Phone | 617 401 9975 |
| Web | https://www.synlogictx.com |
James Collins Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Collins against Synlogic stock is an integral part of due diligence when investing in Synlogic. James Collins insider activity provides valuable insight into whether Synlogic is net buyers or sellers over its current business cycle. Note, Synlogic insiders must abide by specific rules, including filing SEC forms every time they buy or sell Synlogic'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Collins over three months ago Acquisition by James Collins of 62500 shares of Senti Biosciences at 0.31 subject to Rule 16b-3 |
Synlogic Management Efficiency
The company has return on total asset (ROA) of (0.4607) % which means that it has lost $0.4607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5875) %, meaning that it created substantial loss on money invested by shareholders. Synlogic's management efficiency ratios could be used to measure how well Synlogic manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.8 in 2024. Return On Capital Employed is likely to rise to -0.95 in 2024. At this time, Synlogic's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 12.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 23.4 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Joseph Zakrzewski | AN2 Therapeutics | 62 | |
| MD FACP | AN2 Therapeutics | 76 | |
| WenChen MD | Surrozen | 60 | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| Edward DVM | SAB Biotherapeutics | N/A | |
| Tracy Zimmermann | Generation Bio Co | 54 | |
| Dawn Kalmar | Stoke Therapeutics | 46 | |
| Simona King | Passage Bio | 52 | |
| Mark MD | Passage Bio | 60 | |
| Mark Angelino | Generation Bio Co | 51 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| MS JD | Surrozen | 62 | |
| MBA MPH | Protara Therapeutics | 41 | |
| Jesse Shefferman | Protara Therapeutics | 52 | |
| Christine MBA | SAB Biotherapeutics | 68 | |
| Piergiorgio Donati | AC Immune | 53 | |
| MBA MD | Monopar Therapeutics | 38 | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| Sharon Townson | Monte Rosa Therapeutics | 49 | |
| Mike Zanoni | 4D Molecular Therapeutics | N/A | |
| Raphael MD | 4D Molecular Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.59 | ||||
| Return On Asset | -0.46 |
Synlogic Leadership Team
Elected by the shareholders, the Synlogic's board of directors comprises two types of representatives: Synlogic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Synlogic. The board's role is to monitor Synlogic's management team and ensure that shareholders' interests are well served. Synlogic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Synlogic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Hava, Chief Officer | ||
| Mary Dooley, Head Officer | ||
| Ajay Munshi, Vice Development | ||
| Adam Thomas, Chief Officer | ||
| Michael Jensen, Chief Officer | ||
| Caroline Kurtz, Chief Officer | ||
| Mylene Perreault, VP Research | ||
| Antoine Awad, Principal Officer | ||
| JoseCarlos GutierrezRamos, Advisor | ||
| BAO BCh, CEO Pres | ||
| Elizabeth Wolffe, Head Communications | ||
| James Collins, CoFounder Board | ||
| Brendan Amant, General Secretary | ||
| Molly Harper, Chief Officer | ||
| Neal MD, VP Clinical |
Synlogic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Synlogic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.59 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (11.73) % | ||||
| Current Valuation | (3.48 M) | ||||
| Shares Outstanding | 11.7 M | ||||
| Shares Owned By Insiders | 14.19 % | ||||
| Shares Owned By Institutions | 60.89 % | ||||
| Number Of Shares Shorted | 88.25 K | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 5.02 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Synlogic Stock Analysis
When running Synlogic's price analysis, check to measure Synlogic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synlogic is operating at the current time. Most of Synlogic's value examination focuses on studying past and present price action to predict the probability of Synlogic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synlogic's price. Additionally, you may evaluate how the addition of Synlogic to your portfolios can decrease your overall portfolio volatility.